What is Oramed Pharmaceuticals Inc's earnings per share (EPS)?

Oramed Pharmaceuticals Inc (ORMP) reported diluted earnings per share of $1.50 for fiscal year 2025. This represents a 412.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Oramed Pharmaceuticals Inc Financials

ORMP

Source SEC Filings (10-K/10-Q) Updated Mar 26, 2026 Currency USD FYE March

This page shows Oramed Pharmaceuticals Inc (ORMP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

-0.14x

For every $1 of reported earnings, Oramed Pharmaceuticals Inc generates $-0.14 in operating cash flow (-$9.1M OCF vs $64.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-17.7x

Oramed Pharmaceuticals Inc earns $-17.7 in operating income for every $1 of interest expense (-$15.1M vs $853K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.0M

5Y CAGR-5.9%

Oramed Pharmaceuticals Inc generated $2.0M in revenue in fiscal year 2025.

EBITDA

-$15.0M

YoY-18.9%

Oramed Pharmaceuticals Inc's EBITDA was -$15.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 18.9% from the prior year.

Net Income

$64.0M

YoY+435.3%

Oramed Pharmaceuticals Inc reported $64.0M in net income in fiscal year 2025. This represents an increase of 435.3% from the prior year.

EPS (Diluted)

$1.50

YoY+412.5%

Oramed Pharmaceuticals Inc earned $1.50 per diluted share (EPS) in fiscal year 2025. This represents an increase of 412.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$9.2M

YoY-8.6%

Oramed Pharmaceuticals Inc generated -$9.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 8.6% from the prior year.

Cash & Debt

N/A

Dividends Per Share

$0.25

Oramed Pharmaceuticals Inc paid $0.25 per share in dividends in fiscal year 2025.

Shares Outstanding

40M

YoY+1.3%

5Y CAGR+11.3%

10Y CAGR+13.3%

Oramed Pharmaceuticals Inc had 40M shares outstanding in fiscal year 2025. This represents an increase of 1.3% from the prior year.

Margins & Returns

Gross Margin

0.7%

Oramed Pharmaceuticals Inc's gross margin was 0.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs.

Operating Margin

-754.4%

5Y CAGR-320.6pp

Oramed Pharmaceuticals Inc's operating margin was -754.4% in fiscal year 2025, reflecting core business profitability.

Net Margin

3202.5%

5Y CAGR+3627.3pp

Oramed Pharmaceuticals Inc's net profit margin was 3202.5% in fiscal year 2025, showing the share of revenue converted to profit.

Return on Equity

N/A

Capital Allocation

R&D Spending

$6.4M

YoY+0.9%

5Y CAGR-9.0%

10Y CAGR+2.9%

Oramed Pharmaceuticals Inc invested $6.4M in research and development in fiscal year 2025. This represents an increase of 0.9% from the prior year.

Share Buybacks

$4.7M

YoY+90.9%

Oramed Pharmaceuticals Inc spent $4.7M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 90.9% from the prior year.

Capital Expenditures

$9K

YoY-50.0%

5Y CAGR-35.7%

10Y CAGR+24.6%

Oramed Pharmaceuticals Inc invested $9K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 50.0% from the prior year.

ORMP Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$2.0M	N/A	$1.3M-50.4%	$2.7M0.0%	$2.7M-0.3%	$2.7M
Cost of Revenue	$2.0M	N/A	N/A	N/A	N/A	N/A
Gross Profit	$13K	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$6.4M+0.9%	$6.3M-29.5%	$9.0M-67.5%	$27.6M+31.7%	$21.0M+105.1%	$10.2M
SG&A Expenses	$8.7M+35.0%	$6.5M-23.4%	$8.4M-39.0%	$13.8M+132.6%	$5.9M+40.3%	$4.2M
Operating Income	-$15.1M-18.1%	-$12.8M+18.9%	-$15.8M+61.2%	-$40.6M-67.6%	-$24.2M-106.0%	-$11.8M
Interest Expense	$853K-66.8%	$2.6M+26.2%	$2.0M	N/A	N/A	N/A
Income Tax	$11.3M+255.3%	$3.2M	N/A	$100K	N/A	N/A
Net Income	$64.0M+435.3%	-$19.1M-475.5%	$5.1M+113.9%	-$36.6M-59.0%	-$23.0M-99.7%	-$11.5M
EPS (Diluted)	$1.50+412.5%	$-0.48-442.9%	$0.14+114.9%	$-0.94	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	$2.0M	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	$2.0M	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	$13K	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.2M+11.5%	$1.0M-53.1%	$2.2M	N/A	$2.2M+55.5%	$1.4M+22.3%	$1.2M	N/A
SG&A Expenses	$1.3M-12.4%	$1.5M-36.9%	$2.3M	N/A	$847K-50.0%	$1.7M-5.0%	$1.8M	N/A
Operating Income	-$2.4M+2.5%	-$2.5M+44.7%	-$4.5M	N/A	-$3.1M+1.5%	-$3.1M-5.8%	-$3.0M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	$261K-55.9%	$592K	N/A
Income Tax	$11.1M+8879.4%	-$126K-121.6%	$584K	N/A	$1.1M-30.7%	$1.6M	N/A	N/A
Net Income	$48.4M+264.2%	$13.3M+273.9%	-$7.6M	N/A	-$19.6M-313.0%	$9.2M+499.7%	$1.5M	N/A
EPS (Diluted)	$1.13+264.5%	$0.31+263.2%	$-0.19	N/A	$-0.48-318.2%	$0.22+450.0%	$0.04	N/A

ORMP Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$155.3M-29.6%	$220.6M+36.4%	$161.6M+26.3%	$128.0M+186.8%	$44.6M
Current Assets	N/A	$143.2M-11.9%	$162.6M+3.5%	$157.1M+64.8%	$95.3M+135.3%	$40.5M
Cash & Equivalents	N/A	$54.4M+501.0%	$9.1M-77.6%	$40.5M-47.6%	$77.2M+300.3%	$19.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$9.0M-84.1%	$56.7M+477.1%	$9.8M-19.6%	$12.2M+4.0%	$11.8M
Current Liabilities	N/A	$5.7M-89.3%	$53.2M+826.1%	$5.7M-14.0%	$6.7M+47.2%	$4.5M
Long-Term Debt	N/A	N/A	N/A	$25K-99.8%	$12.5M	N/A
Total Equity	N/A	$146.3M-10.7%	$163.8M+7.9%	$151.8M+31.1%	$115.8M+252.1%	$32.9M
Retained Earnings	N/A	-$176.6M-12.1%	-$157.6M+3.4%	-$163.1M-42.0%	-$114.9M-24.0%	-$92.6M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$220.5M+36.4%	$161.7M+9.6%	$147.5M-5.0%	$155.3M-5.9%	$165.1M-10.4%	$184.2M-9.5%	$203.7M-7.7%	$220.6M
Current Assets	$136.1M+37.5%	$99.0M-24.7%	$131.5M-8.2%	$143.2M+0.3%	$142.8M-6.8%	$153.3M-13.5%	$177.1M+8.9%	$162.6M
Cash & Equivalents	$52.2M+230.3%	$15.8M-78.8%	$74.5M+36.9%	$54.4M+29.3%	$42.1M-50.3%	$84.8M+356.3%	$18.6M+105.1%	$9.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$17.2M+140.5%	$7.2M+6.4%	$6.7M-25.4%	$9.0M+4.3%	$8.6M+20.7%	$7.2M-80.7%	$37.0M-34.8%	$56.7M
Current Liabilities	$6.1M+65.7%	$3.7M-32.8%	$5.5M-3.4%	$5.7M+7.8%	$5.3M+41.3%	$3.7M-88.9%	$33.6M-36.9%	$53.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$203.3M+31.5%	$154.5M+9.7%	$140.8M-3.7%	$146.3M-6.5%	$156.4M-11.6%	$177.1M+6.3%	$166.6M+1.7%	$163.8M
Retained Earnings	-$122.6M+28.3%	-$171.0M+7.2%	-$184.3M-4.3%	-$176.6M-6.1%	-$166.4M-13.4%	-$146.8M+5.9%	-$156.0M+1.0%	-$157.6M

ORMP Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$9.1M-8.7%	-$8.4M+18.3%	-$10.3M+63.1%	-$27.9M-31.8%	-$21.2M-70.3%	-$12.4M
Capital Expenditures	$9K-50.0%	$18K-92.9%	$254K-48.8%	$496K+32.3%	$375K+357.3%	$82K
Free Cash Flow	-$9.2M-8.6%	-$8.4M+20.1%	-$10.5M+62.9%	-$28.4M-31.8%	-$21.6M-72.1%	-$12.5M
Investing Cash Flow	$5.4M-94.9%	$105.8M+244.9%	-$73.0M-341.8%	$30.2M+227.1%	-$23.8M-613.7%	$4.6M
Financing Cash Flow	-$4.7M+90.9%	-$52.0M-200.1%	$52.0M+382.2%	$10.8M-89.5%	$102.9M+332.6%	$23.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$4.7M+90.9%	$2.5M	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$1.6M+54.0%	-$3.5M-0.5%	-$3.5M-84.1%	-$1.9M+73.1%	-$7.1M-442.1%	$2.1M+240.7%	-$1.5M-4.1%	-$1.4M
Capital Expenditures	$0-100.0%	$4K+33.3%	$3K-72.7%	$11K+120.0%	$5K	$0-100.0%	$2K-33.3%	$3K
Free Cash Flow	-$1.6M+54.1%	-$3.5M-0.5%	-$3.5M-83.2%	-$1.9M+73.0%	-$7.1M-442.3%	$2.1M+240.5%	-$1.5M-4.0%	-$1.4M
Investing Cash Flow	$38.4M+169.9%	-$54.9M-332.3%	$23.6M+53.1%	$15.4M+145.0%	-$34.3M-136.2%	$94.7M+215.5%	$30.0M0.0%	$30.0M
Financing Cash Flow	-$361K	N/A	N/A	-$1.2M+7.4%	-$1.3M+95.8%	-$30.6M-60.8%	-$19.0M+24.0%	-$25.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$361K	N/A	N/A	$1.2M	N/A	N/A	N/A	N/A

ORMP Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	0.7%	N/A	N/A	N/A	N/A	N/A
Operating Margin	-754.4%	N/A	-1176.8%+325.2pp	-1502.0%-605.8pp	-896.1%-462.3pp	-433.8%
Net Margin	3202.5%	N/A	379.7%+1732.3pp	-1352.6%-502.1pp	-850.5%-425.7pp	-424.8%
Return on Equity	N/A	-13.1%-16.2pp	3.1%+27.2pp	-24.1%-4.2pp	-19.9%+15.2pp	-35.0%
Return on Assets	N/A	-12.3%-14.6pp	2.3%+24.9pp	-22.6%-4.7pp	-18.0%+7.8pp	-25.8%
Current Ratio	N/A	25.19+22.1	3.06-24.3	27.34+13.1	14.27+5.3	8.93
Debt-to-Equity	N/A	0.06-0.3	0.35+0.3	0.00-0.1	0.11-0.2	0.36
FCF Margin	-457.7%	N/A	-787.2%+264.0pp	-1051.2%-253.7pp	-797.5%-335.4pp	-462.1%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	0.7%	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	-225.0%	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	-382.1%	N/A	N/A	N/A	N/A	N/A
Return on Equity	23.8%+15.2pp	8.6%+14.0pp	-5.4%	N/A	-12.5%-17.7pp	5.2%+4.3pp	0.9%	N/A
Return on Assets	21.9%+13.7pp	8.2%+13.4pp	-5.2%	N/A	-11.9%-16.9pp	5.0%+4.3pp	0.8%	N/A
Current Ratio	22.25-4.6	26.81+2.9	23.94-1.3	25.19-1.9	27.08-14.0	41.06+35.8	5.28+2.2	3.06
Debt-to-Equity	0.08+0.0	0.050.0	0.05-0.0	0.060.0	0.06+0.0	0.04-0.2	0.22-0.1	0.35
FCF Margin	N/A	N/A	-176.1%	N/A	N/A	N/A	N/A	N/A

Similar Companies

HilleVax, Inc. HLVX

$104.8M

Mei Pharma Inc MEIP

$100.8M

Fortress Biotech Inc FBIO

$81.5M

Adagene Inc. ADAG

$188.1M

Spero Therapeuti SPRO

$140.7M

Frequently Asked Questions

What is Oramed Pharmaceuticals Inc's annual revenue?

Oramed Pharmaceuticals Inc (ORMP) reported $2.0M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Oramed Pharmaceuticals Inc profitable?

Yes, Oramed Pharmaceuticals Inc (ORMP) reported a net income of $64.0M in fiscal year 2025, with a net profit margin of 3202.5%.

What is Oramed Pharmaceuticals Inc's EBITDA?

Oramed Pharmaceuticals Inc (ORMP) had EBITDA of -$15.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Oramed Pharmaceuticals Inc's gross margin?

Oramed Pharmaceuticals Inc (ORMP) had a gross margin of 0.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Oramed Pharmaceuticals Inc's operating margin?

Oramed Pharmaceuticals Inc (ORMP) had an operating margin of -754.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Oramed Pharmaceuticals Inc's net profit margin?

Oramed Pharmaceuticals Inc (ORMP) had a net profit margin of 3202.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Oramed Pharmaceuticals Inc pay dividends?

Yes, Oramed Pharmaceuticals Inc (ORMP) paid $0.25 per share in dividends during fiscal year 2025.

What is Oramed Pharmaceuticals Inc's free cash flow?

Oramed Pharmaceuticals Inc (ORMP) generated -$9.2M in free cash flow during fiscal year 2025. This represents a -8.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Oramed Pharmaceuticals Inc's operating cash flow?

Oramed Pharmaceuticals Inc (ORMP) generated -$9.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Oramed Pharmaceuticals Inc's capital expenditures?

Oramed Pharmaceuticals Inc (ORMP) invested $9K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Oramed Pharmaceuticals Inc spend on research and development?

Oramed Pharmaceuticals Inc (ORMP) invested $6.4M in research and development during fiscal year 2025.

Does Oramed Pharmaceuticals Inc buy back shares?

Yes, Oramed Pharmaceuticals Inc (ORMP) spent $4.7M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Oramed Pharmaceuticals Inc have outstanding?

Oramed Pharmaceuticals Inc (ORMP) had 40M shares outstanding as of fiscal year 2025.

Are Oramed Pharmaceuticals Inc's earnings high quality?

Oramed Pharmaceuticals Inc (ORMP) has an earnings quality ratio of -0.14x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Oramed Pharmaceuticals Inc cover its interest payments?

Oramed Pharmaceuticals Inc (ORMP) has an interest coverage ratio of -17.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.